Who is sponsoring NCT01202552?

NCT01202552 is sponsored by Queen Saovabha Memorial Institute.

What drugs are being tested in NCT01202552?

Interventions: seasonal influenza vaccine, seasonal influenza vaccine, seasonal influenza vaccine.

What is the status of NCT01202552?

NCT01202552 is currently COMPLETED.

Last reviewed 2018-04-05 · How we verify

Two-site Intradermal Influenza Vaccination in Elderly

NCT01202552 NA COMPLETED

One-site dose sparing intradermal influenza vaccination in elderly had been studied but resulted in unsatisfactory outcomes. The investigators evaluate the safety and immunogenicity of the two-site intradermal injection of influenza vaccine containing all 6 and 12 micrograms of hemagglutinin antigen per strain (with 4/10th and 8/10th of a regular 15 microgram HA/strain intramuscular vaccine respectively) in elderly over 60 years of age. An influenza vaccine administered intramuscularly at the standard dose is used as the reference vaccine.

Details

Lead sponsor	Queen Saovabha Memorial Institute
Phase	NA
Status	COMPLETED
Enrolment	180
Start date	2010-10
Completion	2018-04

Conditions

Influenza

Interventions

seasonal influenza vaccine
seasonal influenza vaccine
seasonal influenza vaccine

Primary outcomes

immunogenicity — 4 months
evaluate the immunogenicity of the two-site intradermal influenza vaccination containing all 6 and 12 micrograms of hemagglutinin antigen per strain (with 4/10th and 8/10th of a regular 15 microgram HA/strain intramuscular vaccine respectively) in elderly over 60 years of age , as measured by the titer of hemagglutination inhibition (HAI) antibodies, in order to determine whether it would meet the guidelines of the European Committee for Proprietary Medicinal Products (CPMP) for the annual relicensure of influenza vaccines

Countries

Thailand